Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: A retrospective study of 47 patients

Journal of the American Academy of Dermatology

Volumn 68, Issue 3, 2013, Pages 404-411

  Leshem, Yael A ^a,b   Hodak, Emmilia ^a,b   David, Michael ^a,b   Anhalt, Grant J ^c   Mimouni, Daniel ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

autoimmune bullous disease; pemphigus; rheumatoid arthritis; rituximab; treatment

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DAPSONE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE EXACERBATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; INFUSION RELATED REACTION; MALE; MULTIPLE CYCLE TREATMENT; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TINEA CORPORIS; TREATMENT RESPONSE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PEMPHIGUS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84873712428     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.08.010     Document Type: Article

References (32)

1. J.R. Stanley Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases J Clin Invest 83 1989 1443 1448
2. A.S. Payne, Y. Hanakawa, M. Amagai, and J.R. Stanley Desmosomes and disease: pemphigus and bullous impetigo Curr Opin Cell Biol 16 2004 536 543
3. M. Amagai, V. Klaus-Kovtun, and J.R. Stanley Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion Cell 67 1991 869 877
4. R.S. Lester, S.R. Knowles, and N.H. Shear The risks of systemic corticosteroid use Dermatol Clin 16 1998 277 278
5. L.K. Martin, V. Werth, E. Villanueva, J. Segall, and D.F. Murrell Interventions for pemphigus vulgaris and pemphigus foliaceus Cochrane Database Syst Rev 1 2009 CD006263
6. S. Beissert, D. Mimouni, A.J. Kanwar, N. Solomons, V. Kalia, and G.J. Anhalt Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial J Invest Dermatol 130 2010 2041 2048
7. T.G. Salopek, S. Logsetty, and E.E. Tredget Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder J Am Acad Dermatol 47 2002 785 788
8. P. Joly, H. Mouquet, J.C. Roujeau, M. D'Incan, D. Gilbert, and S. Jacquot A single cycle of rituximab for the treatment of severe pemphigus N Engl J Med 357 2007 545 552
9. J.H. Kim, Y.H. Kim, M.R. Kim, and S.C. Kim Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients Br J Dermatol 165 2011 646 651
10. M. Kasperkiewicz, I. Shimanovich, R.J. Ludwig, C. Rose, D. Zillikens, and E. Schmidt Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients J Am Acad Dermatol 65 2011 552 558
11. G. Cianchini, R. Corona, A. Frezzolini, M. Ruffelli, B. Didona, and P. Puddu Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature Arch Dermatol 143 2007 1033 1038
12. A.R. Ahmed, Z. Spigelman, L.A. Cavacini, and M.R. Posner Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin N Engl J Med 355 2006 1772 1779
13. A. Nagel, M. Hertl, and R. Eming B-cell-directed therapy for inflammatory skin diseases J Invest Dermatol 129 2009 289 301
14. M.J. Leandro, G. Cambridge, M.R. Ehrenstein, and J.C. Edwards Repopulation of B lymphocytes in peripheral blood following B lymphocyte depletion with rituximab in rheumatoid arthritis Arthritis Rheum 54 2006 613 620
15. D.G. Maloney, A.J. Grillo-López, C.A. White, D. Bodkin, R.J. Schilder, and J.A. Neidhart IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood 90 1997 2188 2195
16. J.C. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, and D.R. Close Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 350 2004 2572 2581
17. S.B. Cohen, P. Emery, M.W. Greenwald, M. Dougados, R.A. Furie, and M.C. Genovese Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum 54 2006 2793 2806
18. P. Emery, R. Fleischmann, A. Filipowicz-Sosnowska, J. Schechtman, L. Szczepanski, and A. Kavanaugh The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial Arthritis Rheum 54 2006 1390 1400
19. P. Emery, P.J. Mease, A. Rubbert-Roth, J.R. Curtis, U. Müller-Ladner, and N.B. Gaylis Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis Rheumatology (Oxford) 50 2011 2223 2232
20. D.F. Murrell, S.D. Dick, A.R. Ahmed, A. Amagai, M.A. Barnadas, and L. Borradori Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus J Am Acad Dermatol 58 2008 1043 1046
21. D. Mimouni, C.H. Nousari, D.L. Cummins, D.J. Kouba, M. David, and G.J. Anhalt Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris J Am Acad Dermatol 49 2003 1059 1062
22. G.J. Anhalt, R.S. Labib, J.J. Voorhees, T.F. Beals, and L.A. Diaz Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease N Engl J Med 306 1982 1189 1196
23. E. Schmidt, M. Goebeler, and D. Zillikens Rituximab in severe pemphigus Ann N Y Acad Sci 1173 2009 683 691
24. B. Horváth, J. Huizinga, H.H. Pas, A.B. Mulder, and M.F. Jonkman Low dose rituximab is effective in pemphigus Br J Dermatol 166 2012 405 412
25. A. Faurschou, and R. Gniadecki Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris Int J Dermatol 47 2008 292 294
26. A.S. Belgi, M. Azeez, C. Hoyle, and R.E. Williams Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed Clin Exp Dermatol 31 2006 143
27. A.V. Marzano, D. Fanoni, L. Venegoni, E. Berti, and R. Caputo Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab) Dermatology 214 2007 310 318
28. A. Dupuy, M. Viguier, C. Bédane, F. Cordoliani, S. Blaise, and F. Aucouturier Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody) Arch Dermatol 140 2004 91 96
29. M. Hertl, D. Zillikens, L. Borradori, L. Bruckner-Tuderman, H. Burckhard, and R. Eming Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases J Dtsch Dermatol Ges 6 2008 366 373
30. A.J. Kanwar, D. Tsuruta, K. Vinay, H. Koga, N. Ishii, and T. Dainichi Efficacy and safety of rituximab treatment in Indian pemphigus patients J Eur Acad Dermatol Venereol 2011 [Epub ahead of print]
31. H. Green, M. Paul, L. Vidal, and L. Leibovici Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients Cochrane Database Syst Rev 3 2007 CD005590
32. M. Hertl, R. Eming, and L. Borradori Rituximab (anti-CD20 monoclonal antibody)-ultimate or first choice in pemphigus? Dermatology 214 2007 275 277